North America Neurological Biomarkers Market Size, Share & Industry Trends Analysis Report By Type (Proteomic, Genomic, Metabolomic), By Application (Alzheimer's Disease, Parkinson’s Disease and Multiple Sclerosis), By Country and Growth Forecast, 2022 - 2028

Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 North America Neurological Biomarkers Market, by Type
1.4.2 North America Neurological Biomarkers Market, by Application
1.4.3 North America Neurological Biomarkers Market, by Country
1.5 Methodology for the research

Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition & Scenarios
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints

Chapter 3. North America Neurological Biomarkers Market by Type
3.1 North America Proteomic Market by Country
3.2 North America Genomic Market by Country
3.3 North America Metabolomic Market by Country
3.4 North America Others Market by Country

Chapter 4. North America Neurological Biomarkers Market by Application
4.1 North America Alzheimer's Disease Market by Country
4.2 North America Parkinson’s Disease Market by Country
4.3 North America Multiple Sclerosis Market by Country

Chapter 5. North America Neurological Biomarkers Market by Country
5.1 US Neurological Biomarkers Market
5.1.1 US Neurological Biomarkers Market by Type
5.1.2 US Neurological Biomarkers Market by Application
5.2 Canada Neurological Biomarkers Market
5.2.1 Canada Neurological Biomarkers Market by Type
5.2.2 Canada Neurological Biomarkers Market by Application
5.3 Mexico Neurological Biomarkers Market
5.3.1 Mexico Neurological Biomarkers Market by Type
5.3.2 Mexico Neurological Biomarkers Market by Application
5.4 Rest of North America Neurological Biomarkers Market
5.4.1 Rest of North America Neurological Biomarkers Market by Type
5.4.2 Rest of North America Neurological Biomarkers Market by Application

Chapter 6. Company Profiles
6.1 F. Hoffmann-La Roche Ltd.
6.1.1 Company Overview
6.1.2 Financial Analysis
6.1.3 Segmental and Regional Analysis
6.1.4 Research & Development Expense
6.2 Bio-Rad laboratories, Inc.
6.2.1 Company Overview
6.2.2 Financial Analysis
6.2.3 Segmental and Regional Analysis
6.2.4 Research & Development Expenses
6.3 Merck Group
6.3.1 Company Overview
6.3.2 Financial Analysis
6.3.3 Segmental and Regional Analysis
6.3.4 Research & Development Expense
6.3.5 Recent strategies and developments:
6.3.5.1 Partnerships, Collaborations, and Agreements:
6.4 PerkinElmer, Inc.
6.4.1 Company Overview
6.4.1 Financial Analysis
6.4.2 Segmental and Regional Analysis
6.4.3 Research & Development Expense
6.5 Shimadzu Corporation
6.5.1 Company Overview
6.5.2 Financial Analysis
6.5.3 Segmental and Regional Analysis
6.6 Thermo Fisher Scientific, Inc.
6.6.1 Company Overview
6.6.2 Financial Analysis
6.6.3 Segmental and Regional Analysis
6.6.4 Research & Development Expense
6.7 BioMérieux S.A.
6.7.1 Company Overview
6.7.2 Financial Analysis
6.7.3 Segmental and Regional Analysis
6.7.4 Research & Development Expenses
6.8 Myriad Genetics, Inc.
6.8.1 Company Overview
6.8.2 Financial Analysis
6.8.3 Segmental Analysis
6.8.4 Research & Development Expenses
6.9 Quanterix Corporation
6.9.1 Company Overview
6.9.2 Financial Analysis
6.9.3 Segmental and Regional Analysis
6.9.4 Research & Development Expenses
6.9.5 Recent strategies and developments:
6.9.5.1 Partnerships, Collaborations, and Agreements:
6.10. Neuro-Bio Ltd.
6.10.1 Company Overview